skip to Main Content

200 million major medical annual procedures globally (WHO)

Last year, doctors spent $100 million on contact devices (dyes or probes) to assess adequacy of blood flow in heart bypass, vascular, transplants, plastics, & general surgeries. Market growth is over 12%.

Scinovia announces 1st-of-its-kind, state-of-the-art biophotonics device for real-time, non-contact visualization of measurements across vessels & tissue–no hassles with chemical injections or probes or synchronizing with instruments.

10 renowned surgeons comprise Scinovia Medical Advisory Board

rol-e
  • This field is for validation purposes and should be left unchanged.
PLATFORM TECHNOLOGY

Various form factors from NOVIA platform technology

product_line_roadmap_v1-600a-vert
PRODUCT MILESTONES

2015

  • Developed breakthrough capability for non-contact measurement of fast to slow blood flow speeds in vessels at or near the surface

2016

  • Testing in various vet surgeries
  • Preparing for regulatory submission – CE Mark & US FDA Class II, 510(k) strategy & draft application (by former FDA Branch Chief)

2017

  • Finished product
  • External testing

2018 targets

  • Gen-1 Regulatory clearance in US, EU
  • Commercialization
  • Gen-2 Regulatory submission EU, US, CA, JP
.

Scinovia Corp

Europe, US, Singapore

info @ Scinovia com

Back To Top